OBJECTIVES: Medication errors are the most significant cause of medical injuries. In an attempt to reduce infusion errors, smart pumps were developed. These new infusion systems include hospital defined drug libraries with established dosing limits and other clinical advisories integrated into the system. The INFUSOMAT® SPACE + the CENTRAL ALARM MANAGEMENT, OneView® is an infusion + a monitoring system that offers clinical and economic benefits by increase safety in delivering IV medications, reducing hospital length of stay, providing an advanced or faster response to emergencies and improving workflows in the ICU. This analysis aims to estimate the economic impact of this new system on driving care toward evidence-based standards from the perspective of public health system (IMSS).  METHODS: An economic impact analysis was developed. In order to obtain system efficacy and safety evidence, a literature search was driven. For medical errors in Mexico associated to infusion pumps, a retrospective analysis of medical claims during the last 4 years was conducted utilizing data from the National Commission of Medical Arbitration (CONAMED). Costs of ICU per day and adverse events were obtained from the IMSS Finance Direction and the Groups Related to Diagnosis (GRD). Costs were reported in US dollars (1 USD = 15.42 MXN). RESULTS: The use of the INFUSOMAT® SPACE + CENTRAL ALARM MANAGEMENT (ONE VIEW) in comparison with the current infusion pumps used in the IMSS, lead to better benefits, clinical and economic. In adverse events avoided due the lack of monitoring (5% reduction) and the expected length hospital stay (2.4% lower). Such reduction could represents $99,984,542 USD and $4,999,227 USD in savings for the IMSS per year, respectively. CONCLUSIONS: Adopting the INFUSOMAT® SPACE + CENTRAL ALARM MANAGEMENT (ONE VIEW) will reduce adverse events and will significant lower the costs associated with longer patient stays and complications at the IMSS ICU.